Company intelligence / Profile preview

DNX Biopharmaceuticals

San Diego, California, USA

Ownership: Private
Development stage: Other

Overview

DNX Biopharmaceuticals is developing long-acting, non-immunogenic therapeutic proteins for inflammatory and oncologic disorders. Several programs are in preclinical stages, including candidates designed as immune checkpoint inhibitors for cancer immunotherapy, with prior assets entering nonclinical or discontinued stages in other indications. The company has a strategic partnership with Johnson & Johnson’s Lung Cancer Initiative[1][3][5][6].

Therapeutic areas: OncologyRheumatologyOphthalmologyImmunology
Modalities: ProteinBiologicMonoclonal antibodyRecombinant proteinAntibodyImmune checkpoint inhibitor
Industry: Biotech

Drug pipeline

1 asset

DNX-114

Preclinical

Partnerships

XL-proteinJohnson & Johnson Innovation – JLABSLung Cancer Initiative at Johnson & Johnson

Beyond the preview

Go deeper on DNX Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNX Biopharmaceuticals.

Explore the full profile